ABL1 and lung carcinoma: Expression of a drug‐resistant mutant of ABL1 fully rescues the drug‐induced cell death and siRNA‐mediated depletion of ABL1 significantly reduces cell viability, validating the specificity of ABL inhibitors and highlighting the importance of mutationally altered ABL1 in lung cancer cells.